Navigation Links
Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award
Date:10/29/2008

Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award.

A vaccine developed by University of Melbourne researchers that could eradicate a fatal form of brain disease will be delivered to Peru next week, and could soon be commercially available thanks to multi-million dollar funding.

The parasite Taenia solium causes 50 million tapeworm infections and 50,000 deaths from brain disease in the developing world each year. A major cash injection from the British Government and the Bill and Melinda Gates Foundation means that the vaccine will be registered and be produced on a commercial scale.

Although tapeworms can grow up to metres long and live in humans for years without health implications, their eggs can travel to the brain and cause paralysis and the often fatal condition of neurocysticercosis.

The disease results in cysts on the brain and spinal column, which is the most common cause of acquired epilepsy in the developing world and more than half the world's population living in countries where the parasite is endemic.

Professor Marshall Lightowlers at the Faculty of Veterinary Science has been striving towards the parasite's eradication for almost 30 years.

"I'm in a very lucky position that a lot of people dream and talk about, but virtually nobody reaches," said Professor Lightowlers.

"This disease has been identified as one that could be eradicated from the globe, so this is a very significant hurdle which means the end is well and truly in sight."

Five field trials were carried out in Peru, Cameroon, Mexico and Honduras between 2006 and 2008. All five trials achieved greater than 99% success.

The field trials have proved so successful that the team has been asked to provide 210,000 doses of the vaccine for a separate US$15.7m project funded by the Gates Foundation in Northern Peru, with the first of these doses arriving next week.

They will be used to treat 100,000 pigs in an area where the same number of humans are at risk of contracting the disease in the largest field trial of the vaccine to date.

Professor Lightowlers and his colleagues will travel to the infected regions where they have already trained local people to carry out the vaccinations; some from countries including Peru and Cameroon are now completing doctorates at the University.

University of Melbourne researchers have chosen to immunize pigs instead of humans with two intermuscular injections for piglets that prevent the animals from ever becoming infected but does not remove the disease from animals already infected.

"If we can prove that we can produce the vaccine commercially in a way that works in the field we will be looking at philanthropic groups for whom $100 million or $200 million isn't a lot of money to pay for the millions of doses needed to vaccinate pigs across the globe," he said.

In countries without proper sanitation, and where pigs and humans live in close quarters, there is a constant cycle of re-infection.

Pigs contract the tapeworm parasite from contact with human faeces, it is then passed on to humans who eat improperly cooked pig meat, and then more seriously, from human to human via exposure to tapeworm eggs in human faeces.

The vaccine will be developed and registered for commercial use by UK-based GALVmed, an organisation dedicated to the development of diagnostics, vaccines and medicines to tackle livestock diseases across the world.

GALVmed has secured US$28m from the UK Government's Department for International Development and the Gates Foundation for the development of vaccines, of which approximately US$5m is for the Taenia solium vaccine.

Professor Lightowlers says the vaccination could ultimately be delivered directly in humans, but developing it to that point would be a vastly more expensive process and one that would become irrelevant if the disease can be eradicated in pigs.


'/>"/>

Contact: Nerissa Hannink
nhannink@unimelb.edu.au
61-304-305-88055
University of Melbourne
Source:Eurekalert

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Computers help chemists fight emerging infections
3. Study shines more light on benefit of vitamin D in fighting cancer
4. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
5. HIV Drug Might Fight Cancer
6. ADA Challenges Marylanders to Step Out to Fight Diabetes Epidemic
7. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
8. Drug, Pacemaker Fight Irregular Heartbeat
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. The fight against colorectal cancer
11. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: